Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ASC30 + ASC39
- Development stage
- Preclinical
- Lead developer
- Ascletis Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
ASC30 + ASC39 (also known as ASC30_39FDC) is an investigational, once-daily oral fixed-dose combination tablet being developed by Ascletis Pharma for the treatment of obesity and chronic weight management. The combination consists of two small molecule active ingredients: ASC30, a glucagon-like peptide-1 receptor (GLP-1R) agonist, and ASC39, a selective amylin receptor agonist (SARA). By targeting both the GLP-1 and amylin pathways, the combination aims to achieve synergistic appetite suppression and weight loss. Preclinical studies in non-human primates demonstrated a body weight reduction of approximately 6.9% after a seven-day treatment. Ascletis expects to submit an Investigational New Drug (IND) application to the U.S. FDA for the combination in the third quarter of 2026, with plans to enter clinical development in the fourth quarter of 2026.
- Other names
- ASC30 + ASC39
02
Targets
Beyond the preview
Go deeper on ASC30 + ASC39.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ASC30 + ASC39.